Company profile
Cardiff Oncology, Inc.
NASDAQ:CRDFBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ONVANSERTIB | phase2 | — | 6 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03414034 | phase2 | completed | 2018-08-14 | 2023-10-16 | Cardiff Oncology | Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer |
| NCT03303339 | phase1_2 | completed | 2017-11-17 | 2021-11-17 | Cardiff Oncology | Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) |
| NCT03829410 | phase1_2 | completed | 2019-06-24 | 2024-01-29 | Cardiff Oncology | Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation |
| NCT04752696 | phase2 | completed | 2021-05-25 | 2024-12-24 | Cardiff Oncology | Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma |
| NCT05593328 | phase2 | completed | 2023-03-17 | 2024-12-09 | Cardiff Oncology | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation |
FDA applications (0)
No records yet.